R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...
Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility expansion. DELFT, Netherlands, March 12, 2026 /PRNewswire/ -- ...
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth ...
SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...
PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...
GenScript Biotech Corporation continues to scale platform synergies, global reach, and automation-enabled operations, with revenue reaching US$959.5 million (+61.4% YoY); adjusted net profit rising up ...
As of December 31, 2023, 88,700 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results